---
title: Brookfield (BN) — Wall Street analysts' targets, grades and estimates
canonical: https://sweetvaluelab.com/stocks/bn/analysts
ticker: BN
as_of: 2026-11-02
sector: Financial Services
---
# Brookfield (BN) — Wall Street analysts

6 firms published a price target for BN in the last 12 months. Counting each firm once, at its latest, the median target is $56.50, 44% above the last close of $39.28 (Oct 30, 2026); the lowest is $49.00 and the highest $61.00.

These are the analysts' figures, quoted, not this site's. The site's own model value for BN is on the valuation page: https://sweetvaluelab.com/stocks/bn/valuation.

## At a glance

| Figure | Value |
| --- | ---: |
| Median target (each firm's latest, last 12 months) | $56.50 |
| Median target vs last close | +44% |
| Firms with a target, last 12 months | 6 |
| Lowest – highest target | $49.00 – $61.00 |
| Current grades of 6 firms: positive / neutral / negative | 6 / 0 / 0 |
| Upgrades / downgrades, last 12 months | 0 / 0 |
| Consensus revenue growth, next 3 fiscal years | −50% a year |

## Each firm's latest target (last 12 months)

Newest first. Change is against the same firm's previous target; the last two columns are the target against the close on the day it was published and against the last close.

| Date | Firm | Target | Previous | Change | Vs price then | Vs price now | Report |
| --- | --- | ---: | ---: | ---: | ---: | ---: | --- |
| 2026-08-14 | Scotiabank | $54.00 | $53.00 | +2% | +24% | +37% | https://thefly.com/ajax/news_get.php?id=4411812 |
| 2026-07-21 | Morgan Stanley | $59.00 | $61.00 | −3% | +39% | +50% | https://thefly.com/ajax/news_get.php?id=4388840 |
| 2026-05-19 | TD Securities | $60.00 | — | — | +33% | +53% | https://thefly.com/ajax/news_get.php?id=4357535 |
| 2026-05-15 | RBC Capital | $61.00 | $58.00 | +5% | +34% | +55% | https://thefly.com/ajax/news_get.php?id=4356073 |
| 2025-12-17 | BMO Capital | $49.00 | — | — | +9% | +25% | https://www.streetinsider.com/Analyst+Comments/Brookfield+Corporation+%28BN%29+PT+Raised+to+%2449+at+BMO+Capital/25748960.html |
| 2025-11-14 | CIBC | $52.00 | — | — | +19% | +32% | https://thefly.com/permalinks/entry.php/id4240254/6945286394/BN-Brookfield-Corp-price-target-raised-by--at-CIBC-heres-why |

## Current grades (each firm's latest, last 12 months)

| As of | Firm | Grade |
| --- | --- | --- |
| 2026-08-14 | Scotiabank | “Sector Outperform” |
| 2026-07-21 | Morgan Stanley | “Overweight” |
| 2026-05-15 | RBC Capital | “Outperform” |
| 2026-05-12 | J.P. Morgan | “Overweight” |
| 2025-11-14 | TD Securities | “Buy” |
| 2025-11-14 | CIBC | “Outperform” |

## Grade changes (last 24 months)

None in the last 24 months.

2 older changes are listed on the page.

## Consensus estimates by fiscal year

A reported year shows the company's revenue and GAAP diluted EPS with the consensus beside it; a later year shows the consensus average and its range. The analysts' EPS usually leaves items such as stock compensation out, so reported and estimated EPS are not like for like.

| Fiscal year | Status | Revenue | YoY | EPS | YoY | Consensus revenue | Consensus EPS | Analysts |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| 2021 | reported | $75.7B | +21% | $1.59 | — | $4.5B (reported +1568% vs it) | $1.96 | 1 |
| 2022 | reported | $92.8B | +22% | $0.79 | −50% | $3.9B (reported +2252% vs it) | $1.77 | 1 |
| 2023 | reported | $95.9B | +3% | $0.41 | −49% | $4.5B (reported +2053% vs it) | $1.91 | 1 |
| 2024 | reported | $86.0B | −10% | $0.21 | −49% | $5.5B (reported +1470% vs it) | $2.39 | 1 |
| 2025 | reported | $76.1B | −11% | $0.50 | +142% | $8.2B (reported +830% vs it) | $2.43 | 1 |
| 2026 | estimate | $7.2B | −90% | $2.76 | +13% | $7.1B – $7.4B | $2.69 – $2.81 | 1 |
| 2027 | estimate | $8.9B | +23% | $3.40 | +23% | $8.7B – $9.0B | $3.31 – $3.47 | 1 |
| 2028 | estimate | $9.8B | +10% | $3.70 | +9% | $9.6B – $10.0B | $3.62 – $3.79 | 1 |

---

Source: https://sweetvaluelab.com/stocks/bn/analysts (SweetValueLab, free, no account). Targets, grades and estimates are the analysts' own, quoted from Financial Modeling Prep's analyst feeds; reported figures from the company's statements. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.